Qualigen Therapeutics(US:QLGN) Sou Hu Cai Jing·2025-10-28 14:05Core Insights - Qualigen Therapeutics Inc. (QLGN) will rebrand to AIxCrypto after its shareholder meeting on November 12, 2025, and has set three core objectives for 2025 [1][2] Group 1: Business Strategy - QLGN has initiated a new Web3 and cryptocurrency business plan, with the public beta of BesTrade DeAI Agent set to launch at the end of November [1][2] - The first milestone aims to expand the C10 Treasury's asset management scale to $50 million, enhancing its role as a core reserve asset in the Web3 ecosystem [1] - As of October 17, 2023, QLGN's C10 Treasury has completed a $12 million allocation in cryptocurrency assets [1] Group 2: Product Development - The second milestone focuses on accelerating the global growth of BesTrade DeAI Agent, which is designed to optimize trading paths and returns, establishing itself as a leading AI trading platform [2] - The third milestone involves launching the Crypto ecosystem Token on leading exchanges, which will consist of C10 stablecoin and EAI+Crypto products, aiming to create a sustainable on-chain value growth system [2] Group 3: Investment Details - Faraday Future Intelligent Electric Inc. (FFAI), led by founder Jia Yueting, has made a strategic investment in QLGN, with the total investment expected to exceed $41 million, subject to shareholder approval [3] - FFAI invested approximately $30 million for about 55% ownership in QLGN, while Jia Yueting personally invested around $4 million for about 7% ownership [3] - Post-investment, FFAI and Jia Yueting will collectively hold approximately 62% of QLGN, with FFAI gaining significant board representation [3]